Australia markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1600-0.0300 (-0.72%)
At close: 04:00PM EDT
3.9600 -0.20 (-4.81%)
After hours: 06:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1900
Bid0.0000 x 1400
Ask5.0400 x 1300
Day's range4.0850 - 4.2900
52-week range3.9600 - 32.8100
Avg. volume766,480
Market cap255.147M
Beta (5Y monthly)2.11
PE ratio (TTM)N/A
EPS (TTM)-3.3720
Earnings date27 July 2022 - 01 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.33
  • Motley Fool

    Why MacroGenics Stock Is Tanking Today

    Shares of MacroGenics (NASDAQ: MGNX) were tanking by 19.7% as of 12:22 p.m. ET on Wednesday. MacroGenics reported Q1 revenue of $11.1 million, with $3.6 million in sales of breast cancer drug Margenza and the rest from collaborative agreements. It's not surprising that the MacroGenics stock fell after it missed Q1 estimates.

  • Zacks

    MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

    MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

    Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignanciesConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatme